Enveda Biosciences, a biotechnology company using AI to translate nature into new medicines, has announced a new financing round of $55 million to add to its $119 million combined Series B and B1.   New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners.   Enveda’s proprietary platform solves the long-standing obstacles in natura...